Indications for: ADLYXIN
As adjunct to diet and exercise, to improve glycemic control in type 2 diabetes.
Limitations of Use:
Not studied in patients with chronic pancreatitis or a history of unexplained pancreatitis. Not for treating type 1 diabetes. Not recommended in gastroparesis.
Give by SC inj once daily within the hour prior to first meal into abdomen, thigh, or upper arm; rotate inj sites. Initially 10mcg once daily for 14 days, then 20mcg once daily.
Do not reuse or share pens between patients, even if the needle is changed. History of anaphylaxis or angioedema with another GLP-1 receptor agonist. Discontinue if hypersensitivity reaction occurs. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of pancreatitis: consider alternative antidiabetics. Acute gallbladder disease (eg, cholelithiasis, cholecystitis). Perform gallbladder studies and clinical follow-up if cholelithiasis is suspected. Renal impairment or severe GI reactions: monitor when initiating or escalating doses. ESRD: not recommended. Pregnancy. Nursing mothers.
Glucagon-like peptide-1 (GLP-1) receptor agonist.
Increased risk of hypoglycemia with concomitant sulfonylureas or basal insulin (reduction in their doses may be needed). May affect absorption of oral drugs (delayed gastric emptying). Caution when concomitant oral drugs with narrow therapeutic ratio or that require careful monitoring. Concomitant antibiotics, APAP, other drugs dependent on threshold concentration: administer ≥1hr before Adlyxin; for oral contraceptives, take ≥1hr before or 11hrs after Adlyxin.
Nausea, vomiting, headache, diarrhea, dizziness, hypoglycemia, inj site reactions; anaphylaxis, pancreatitis, renal failure, possibly antibody formation.
Generic Drug Availability:
Starter pack—2 prefilled pens (10mcg + 20mcg); Maintenance pack—2 prefilled pens (20mcg)